Aerie pharmaceuticals reports second quarter 2021 financial results and provides business update

Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq:aeri), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported financial results for the second quarter ended june 30, 2021 and provided a general business update. “our second quarter 2021 results reflect nearly 51 percent growth in net revenues
AERI Ratings Summary
AERI Quant Ranking